Clinical Trial Update: Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing cabazitaxel against abiraterone acetate or enzalutamide in patients with poor-prognosis metastatic castration-resistant prostat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)
• Xtandi (enzalutamide)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Metastatic Castration-Resistant Prostatic Cancer | Phase 2 | Status: UNKNOWN